LL-37
Phase II TrialsAlso known as: Cathelicidin LL-37, CAP18, hCAP18/LL-37
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of hCAP18 and produced primarily by epithelial cells, neutrophils, and macrophages. Research has examined its roles in innate immune defense, wound healing, angiogenesis promotion, and modulation of inflammatory responses, as well as its potential as a therapeutic agent.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Immune Support
- Skin & Wound Healing
LL-37 disrupts bacterial membrane integrity through electrostatic binding and physical membrane destabilization. Beyond antimicrobial activity, research indicates it activates formyl peptide receptor-like 1 (FPRL1/FPR2), promotes keratinocyte migration, induces angiogenesis through VEGF pathway modulation, and modulates TLR-mediated inflammatory signaling.
Has been studied in Phase II trials for wound healing applications. Local tolerability generally acceptable. Systemic safety profile being characterized. Not FDA-approved.
Want to learn more?
Ask Research Chat about LL-37Half-Life
Short (minutes); subject to rapid proteolytic degradation
Administration
topical (in research), subcutaneous injection (in research), intravenous (in research)
Legal Status (US)
Research compound in clinical development. Not FDA-approved.
66 indexed research passages
Related Peptides
Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.
KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.
Larazotide is a synthetic octapeptide that acts as a tight junction regulator in gut epithelium. Research has examined its potential to reduce intestinal permeability ('leaky gut') in celiac disease and other inflammatory gut conditions by antagonizing the zonulin pathway.
Clascoterone is a topical androgen receptor antagonist and the first FDA-approved topical androgen receptor inhibitor, approved for the treatment of acne vulgaris. Research has also examined its potential for androgenetic alopecia given its local antiandrogen activity without the systemic hormonal effects of oral antiandrogens.